News

Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?
The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to ...
Aurobindo Pharma arm Eugia gets USFDA nod for Dasatinib tablets, eyes $1.8 billion market
Eugia Pharma, a subsidiary of Aurobindo Pharma, has secured final USFDA approval for manufacturing and marketing Dasatinib ...
Vietnam Investment Review on MSN11h
Ascletis Reports Positive U S Phase Ib Results for ASC30 Submits Phase IIa Protocol to FDA
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), ...